Compare Bill.com Holdings Inc (BILL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs BIO-TECHNE Corp — how do they compare? Bill.com Holdings Inc trades at $49.68 (market cap $4.91B), while BIO-TECHNE Corp trades at $72.1 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 2.3× Bill.com Holdings Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | TECH | |
|---|---|---|
Market Cap | $4.91B | $11.24B |
Sector | Technology | Health |
52-Week High | $56.32 | $72.29 |
52-Week Low | $31.96 | $43.31 |
Enterprise Value | $4.62B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $47.99, up 2.11% today, with a bullish technical signal from moving averages and strong institutional interest. The company reported revenue growth to $1.46B in 2025 and achieved profitability with net income of $23.80M, marking a significant turnaround from prior losses. Recent news highlights operational efficiency gains from a 30% workforce reduction and strategic focus on AI-driven financial automation for SMBs.
The outlook is positive with consistent earnings beats and analyst consensus favoring a buy rating, though high P/E of 213.91 indicates premium valuation. Key risks include intense fintech competition and reliance on SMB market stability. Upside to the $50.00 high price target depends on sustained margin expansion and successful AI integration.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
